PFPablo Nicolas De Francesco

Pablo Nicolas De Francesco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Nicolas De Francesco has a total of 137 co-authors. Here are the top co-authors by number of shared publications:

  • Mario Perello

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Buenos Aires, Argentina; Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden

    25 shared publications
  • María Paula Cornejo

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [Consejo Nacional de Investigaciones Científicas y Técnicas and Scientific Research Commission, Province of Buenos Aires, National University of La Plata

    11 shared publications
  • Gimena Fernandez

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Argentina

    10 shared publications
  • Franco Barrile

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Argentina

    8 shared publications
  • Agustina Cabral

    Laboratorio de Neurofisiología, Instituto Multidisciplinario de Biología Celular (IMBICE), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional La Plata y Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA), La Plata, Buenos Aires, Argentina

    7 shared publications
  • Mirta Reynaldo

    Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Argentina

    7 shared publications

Latest Publications

  • Open Access

    LEAP2 mediates long-term inhibition of orexigenic neurons of the hypothalamus in mice

    by Lucía Giovanini, María P. Cornejo, Ivana M. Gomez, Nahuel Wanionok, Pablo N. De Francesco, Florencia Heredia, Daniel Castrogiovanni, Leandro Urrutia, German Falasco, Sonia Cantel, et al.

    Liver-expressed antimicrobial peptide 2 (LEAP2) acts via the growth hormone secretagogue receptor (GHSR) to reduce food intake, yet the central mechanisms underlying its anorectic effects remain unclear. Here, we show that circulating LEAP2 accesses discrete brain regions, including the arcuate nucleus of the hypothalamus (ARH), where it targets orexigenic AgRP/NPY neurons. Despite the negligible local expression in the hypothalamus, LEAP2 peptide is detectable in this brain region and in the cerebrospinal fluid, suggesting peripheral origin and central retention. Using fluorescent tracers, in vivo, ex vivo, and in vitro approaches indicate that LEAP2 exhibits prolonged binding to GHSR at the plasma membrane without promoting receptor internalization, thereby limiting subsequent ghrelin action. Using male mice, we found that central or systemic LEAP2 pretreatment results in a sustained inhibition of ghrelin-induced feeding that lasts for several hours after pretreatment. Notably, LEAP2 also suppresses food intake and c-Fos induction triggered by pharmacogenetic activation of AgRP neurons, indicating a broader inhibitory control over these circuits. Together, our findings establish that LEAP2 acts as a persistent inhibitor of hypothalamic orexigenic centers, providing a mechanistic framework for its long-lasting anorectic effects. These results highlight LEAP2 as a key regulator of energy balance and support its potential as a therapeutic target for obesity and metabolic disorders.

  • Open Access

    AgRP neuron activity enhances reward-related consummatory behaviors during energy deficit in mice

    by Daniela A. Cassano, Franco Barrile, Mirta Reynaldo, Gimena Fernandez, María P. Cornejo, María J. Tolosa, María F. Heredia, Nathalia Ferreira, Higor J. Fideles, Pablo N. De Francesco, et al.

    Hunger enhances the consumption of rewarding foods, but the neurobiological basis of this adaptation remains unclear. We hypothesize that agouti-related protein (AgRP) neurons in the hypothalamic arcuate nucleus (ARH) promote the consumption of rewarding stimuli under calorie restriction, independent of caloric content. To test this, we study mice fed 40% of their average daily intake and exposed daily to the non-caloric sweetener saccharin before feeding. We show that calorie-restricted (CR) mice increase saccharin intake before each restricted feeding event and that this response requires ARH integrity. CR mice exhibit activation of AgRP neurons and their brain targets without significant changes in AgRP fiber density. Furthermore, satiated mice increase saccharin intake following chemogenetic activation of AgRP neurons, whereas CR mice with selective chemogenetic inhibition of AgRP neurons show reduced saccharin intake. Thus, we conclude that AgRP neuron activation enhances the consumption of a purely rewarding stimulus in CR mice. These findings contribute to our understanding of how the brain shapes food choices under conditions of energy deficit and could be important for managing food consumption during dieting or in eating disorders.


  • Open Access

    Liraglutide induces enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor

    by Daniela A. Cassano, Julieta Aguggia, Lucía Giovanini, Florencia Heredia, Pablo N. De Francesco, María F. Andreoli, Helgi B. Schöth, Abdella M. Habib, Gimena Fernandez, Mario Perello


  • Open Access

    Growth hormone secretagogue receptor and cannabinoid receptor type 1 intersection in the mouse brain

    by Camila Saenz, Gimena Fernandez, Ramiro Llovera, María J. Tolosa, Sonia Cantel, Jean-Alain Fehrentz, Kenneth Mackie, Lorenzo Leggio, Jeffrey Zigman, Pablo N. De Francesco, et al.

    The growth hormone secretagogue receptor (GHSR) and the cannabinoid receptor type 1 (CB1R) are G-protein coupled receptors highly expressed in the brain and involved in critical regulatory processes, such as energy homeostasis, appetite control, reward, and stress responses. GHSR mediates the effects of both ghrelin and liver-expressed antimicrobial peptide 2, while CB1R is targeted by cannabinoids. Strikingly, both receptors mediate their effects by acting on common brain areas and their individual roles have been well characterized. However, the potential for their co-expression in the same neuronal subsets remains largely unexplored. Here, we aim to map the cell populations where GHSR and CB1R might converge, hypothesizing that their co-expression in specific brain circuits could mediate integrated physiological responses. By utilizing two complementary labeling techniques—GHSR-eGFP mice and Fr-ghrelin labeling of GHSR+ cells—along with specific CB1R immunostaining, we sought to visualize and quantify potential areas of overlap. Also, we analyzed several cell RNA sequencing datasets to estimate the fraction of brain cells expressing both GPCRs and their phenotype. Our neuroanatomical studies revealed evident overlap of GHSR+ and CB1R+ signals in specific neuronal subsets mainly located in the cerebral cortex, hippocampus and the amygdala. Transcriptomic analysis revealed specific subsets of Ghsr+/Cnr1+ glutamatergic neurons in the hippocampus and amygdala, as well as different subtypes of Ghsr+/Cnr1+ neurons in the midbrain, hypothalamus, pons, and medulla. Thus, we revealed that GHSR and CB1R interact differentially across specific regions of the mouse brain, providing new insights into how these receptors' actions are integrated. Current findings may open new avenues for dual therapeutic interventions in metabolic disorders, obesity, and psychiatric conditions.


  • Selective Colocalization of GHSR and GLP-1R in a Subset of Hypothalamic Neurons and Their Functional Interaction

    by Julieta Aguggia, Gimena Fernandez, Daniela Cassano, Emilio R Mustafá, Silvia S Rodríguez, Sonia Cantel, Jean-Alain Fehrentz, Jesica Raingo, Helgi B Schiöth, Abdella M Habib, et al.

    The GH secretagogue receptor (GHSR) and the glucagon-like peptide-1 receptor (GLP-1R) are G protein-coupled receptors with critical, yet opposite, roles in regulating energy balance. Interestingly, these receptors are expressed in overlapping brain regions. However, the extent to which they target the same neurons and engage in molecular crosstalk remains unclear. To explore the potential colocalization of GHSR and GLP-1R in specific neurons, we performed detailed mapping of cells positive for both receptors using GHSR-eGFP reporter mice or wild-type mice infused with fluorescent ghrelin, alongside an anti-GLP-1R antibody. We found that GHSR+ and GLP-1R+ cells are largely segregated in the mouse brain. The highest overlap was observed in the hypothalamic arcuate nucleus, where 15% to 20% of GHSR+ cells were also GLP-1R+ cells. Additionally, we examined RNA-sequencing datasets from mouse and human brains to assess the fraction and distribution of neurons expressing both receptors, finding that double-positive Ghsr+/Glp1r+ cells are highly segregated, with a small subset of double-positive Ghsr+/Glp1r+ cells representing <10% of all Ghsr+ or Glp1r+ cells, primarily enriched in the hypothalamus. Furthermore, we conducted functional studies using patch-clamp recordings in a heterologous expression system to assess potential crosstalk in regulating presynaptic calcium channels. We provide the first evidence that liraglutide-evoked GLP-1R activity inhibits presynaptic channels, and that the presence of one GPCR attenuates the inhibitory effects of ligand-evoked activity mediated by the other on presynaptic calcium channels. In conclusion, while GHSR and GLP-1R can engage in molecular crosstalk, they are largely segregated across most neuronal types within the brain.


  • Open Access

    Hypothalamic tanycytes internalize ghrelin from the cerebrospinal fluid: Molecular mechanisms and functional implications

    by Ivana M. Gomez, Maia Uriarte, Gimena Fernandez, Franco Barrile, Daniel Castrogiovanni, Sonia Cantel, Jean-Alain Fehrentz, Pablo N. De Francesco, Mario Perello


  • GHSR in a Subset of GABA Neurons Controls Food Deprivation-Induced Hyperphagia in Male Mice

    by María Paula Cornejo, Gimena Fernandez, Agustina Cabral, Franco Barrile, Florencia Heredia, Guadalupe García Romero, Juan Pablo Zubimendi Sampieri, Juan Ignacio Quelas, Sonia Cantel, Jean-Alain Fehrentz, et al.

    The growth hormone secretagogue receptor (GHSR), primarily known as the receptor for the hunger hormone ghrelin, potently controls food intake, yet the specific Ghsr-expressing cells mediating the orexigenic effects of this receptor remain incompletely characterized. Since Ghsr is expressed in gamma-aminobutyric acid-producing neurons (GABA neurons), we sought to investigate whether the selective expression of Ghsr in a subset of GABA neurons is sufficient to mediate GHSR’s effects on feeding. First, we crossed mice that express a tamoxifen-dependent Cre recombinase in the subset of GABA neurons that express glutamic acid decarboxylase 2 (Gad2) enzyme (Gad2-CreER mice) with reporter mice, and found that ghrelin mainly targets a subset of Gad2-expressing neurons located in the hypothalamic arcuate nucleus (ARH) and that is predominantly segregated from Agouti-related protein (AgRP)-expressing neurons. Analysis of various single-cell RNA sequencing datasets further corroborated that the primary subset of cells co-expressing Gad2 and Ghsr in the mouse brain are non-AgRP ARH neurons. Next, we crossed Gad2-CreER mice with reactivable GHSR-deficient mice to generate mice expressing Ghsr only in Gad2-expressing neurons (Gad2-GHSR mice). We found that ghrelin treatment induced the expression of the marker of transcriptional activation c-Fos in the ARH of Gad2-GHSR mice, yet failed to induce food intake. In contrast, food deprivation-induced refeeding was higher in Gad2-GHSR mice than in GHSR-deficient mice and similar to wild-type mice, suggesting that ghrelin-independent roles of GHSR in a subset of GABA neurons is sufficient for eliciting full compensatory hyperphagia in mice.


  • Open Access

    Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease

    by Natalia Cecilia Prymaczok, Pablo Nicolas De Francesco, Samanta Mazzetti, Marie Humbert-Claude, Liliane Tenenbaum, Graziella Cappelletti, Eliezer Masliah, Mario Perello, Roland Riek, Juan Atilio Gerez

    Parkinson’s disease is characterized by a progressive accumulation of alpha-Synuclein (αSyn) neuronal inclusions called Lewy bodies in the nervous system. Lewy bodies can arise from the cell-to-cell propagation of αSyn, which can occur via sequential steps of secretion and uptake. Here, by fusing a removable short signal peptide to the N-terminus of αSyn, we developed a novel mouse model with enhanced αSyn secretion and cell-to-cell transmission. Expression of the secreted αSyn in the mouse brain was under the control of a novel hybrid promoter in combination with adeno-associated virus serotype 9 (AAV9). This combination of promoter and viral vector induced a robust expression in neurons but not in the glia of injected mice. Biochemical characterization of the secreted αSyn revealed that, in cultured cells, this protein is released to the extracellular milieu via conventional secretion. The released αSyn is then internalized and processed by acceptor cells via the endosome–lysosome pathway indicating that the secreted αSyn is cell-to-cell transmitted. The secreted αSyn is aggregation-prone and amyloidogenic, and when expressed in the brain of wild-type non-transgenic mice, it induces a Parkinson’s disease-like phenotype that includes a robust αSyn pathology in the substantia nigra, neuronal loss, neuroinflammation, and motor deficits, all the key features of experimental animal models of Parkinson’s disease. In summary, a novel animal model of Parkinson’s disease based on enhanced cell-to-cell transmission of αSyn was developed. The neuron-produced cell-to-cell transmitted αSyn triggers all phenotypic features of experimental Parkinson’s disease in mice.


  • Ghrelin Action in the PVH of Male Mice: Accessibility, Neuronal Targets, and CRH Neurons Activation

    by Gimena Fernandez, Pablo N De Francesco, María P Cornejo, Agustina Cabral, Julieta P Aguggia, Victor J Duque, Nilufer Sayar, Sonia Cantel, Juan I Burgos, Jean-Alain Fehrentz, et al.

    The hormone ghrelin displays several well-characterized functions, including some with pharmaceutical interest. The receptor for ghrelin, the growth hormone secretagogue receptor (GHSR), is expressed in the hypothalamic paraventricular nucleus (PVH), a critical hub for the integration of metabolic, neuroendocrine, autonomic, and behavioral functions. Here, we performed a neuroanatomical and functional characterization of the neuronal types mediating ghrelin actions in the PVH of male mice. We found that fluorescent ghrelin mainly labels PVH neurons immunoreactive for nitric oxide synthase 1 (NOS1), which catalyze the production of nitric oxide [NO]). Centrally injected ghrelin increases c-Fos in NOS1 PVH neurons and NOS1 phosphorylation in the PVH. We also found that a high dose of systemically injected ghrelin increases the ghrelin level in the cerebrospinal fluid and in the periventricular PVH, and induces c-Fos in NOS1 PVH neurons. Such a high dose of systemically injected ghrelin activates a subset of NOS1 PVH neurons, which do not express oxytocin, via an arcuate nucleus–independent mechanism. Finally, we found that pharmacological inhibition of NO production fully abrogates ghrelin-induced increase of calcium concentration in corticotropin-releasing hormone neurons of the PVH whereas it partially impairs ghrelin-induced increase of plasma glucocorticoid levels. Thus, plasma ghrelin can directly target a subset of NO-producing neurons of the PVH that is involved in ghrelin-induced activation of the hypothalamic–pituitary–adrenal neuroendocrine axis.


  • Ghrelin’s orexigenic action in the lateral hypothalamic area involves indirect recruitment of orexin neurons and arcuate nucleus activation

    by Franco Barrile, Daniela Cassano, Gimena Fernandez, Pablo N. De Francesco, Mirta Reynaldo, Sonia Cantel, Jean-Alain Fehrentz, José Donato, Helgi B. Schiöth, Jeffrey M. Zigman, et al.